Vertex discontinues a PhII rare disease drug, sets early 2024 timeline for pivotal non-opioid pain pill readout
07 Nov 2023
Phase 2Clinical Trial Failure
Side effects have led Vertex Pharmaceuticals to stop work on another Phase II drug candidate to treat a rare genetic disease called alpha-1 antitrypsin defiency, or AATD, the biotech disclosed Monday in its third-quarter earnings report.
Vertex is discontinuing research on the small molecule called VX-864 because of “non-serious rash events in some patients,” according to a press release. About three years ago, Vertex abandoned another AATD program, called VX-814, that made it to Phase II after seeing signs of liver damage. Vertex’s stock price moved down about 2% to $379 after markets closed Monday.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.